Sociodemographic or clinical characteristics | Preventing relapse | Preventing disease progression | Side effect risk | Route of administration |
---|---|---|---|---|
Previous DMT treatment | ||||
No | 9.0 (10.5) | 21.8 (13.2) | ||
Yes | 11.3 (10.8) | 27.3 (16.0) | ||
p Value | 0.027 | 0.008 | ||
Incapacity for work | ||||
Partial incapacity | 12.1 (7.5) | |||
Total incapacity | 17.5 (12.8) | |||
Absolute incapacity | 11.8 (7.9) | |||
Incapacity for severe disability | 4.6 (4.8) | |||
Not recognised | 9.6 (6.5) | |||
No incapacity | 10.7 (10.2) | |||
p Value | 0.048 | |||
Anxiety/depression (EQ-5D) | ||||
No | 12.3 (10.1) | |||
Yes | 9.6 (8.5) | |||
p Value | 0.025 | |||
Longer time since MS diagnosis (years) | ||||
<1 | 39.0 (14.4) | |||
1–2 | 17.1 (14.7) | |||
2–5 | 24.0 (16.0) | |||
5–10 | 25.9 (16.7) | |||
10–20 | 30.3 (15.7) | |||
>20 | 21.8 (15.7) | |||
p Value | 0.001 | |||
Greater number of relapses in the past 2 years | ||||
No relapses | 28.4 (15.6) | 23.8 (14.0) | ||
1 relapse | 27.6 (16.7) | 23.9 (15.7) | ||
2 or more relapses | 18.3 (16.6) | 31.1 (16.7) | ||
p Value | 0.005 | 0.030 |
*Only statistically significant results are included (p<0.05).
DMT, disease-modifying therapy; EQ-5D, EuroQol five dimensions questionnaire; MS, multiple sclerosis.